Koronis Pharmaceuticals to present KP-1461 clinical trial data at ICAAC Conference

Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced that clinical trial data demonstrating that the Company's lead HIV drug, KP-1461, resulted in increased HIV mutations consistent with the Viral Decay Acceleration™ mechanism will be featured in a late-breaker oral presentation by James Mullins, Ph.D., Professor of Microbiology and Medicine at the University of Washington, at the upcoming 50^th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Boston, MA.

“First-In-Man Study of the Mutagenic Potential of Nucleoside KP-1461 in HIV-1 Infection”

Dr. Mullins will present an oral, slide presentation, "First-In-Man Study of the Mutagenic Potential of Nucleoside KP-1461 in HIV-1 Infection," on Monday, September 13, at 3:30 p.m. ET at the Boston Convention & Exhibition Center, room 107A (abstract #H-1170a). The presentation will occur in ICAAC session number 113, titled "Clinical and Translational Studies of HIV Therapeutics and Pathogenesis," 1:30 - 4:00 p.m. ET.

KP-1461 is part of a new class of antiviral therapeutics based on a unique mechanism - Viral Decay Acceleration™ (VDA). Unlike other therapeutics that are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to selectively disrupt the HIV genome by further increasing its naturally high rate of mutation to lethal levels with the goal of eventually causing the collapse of the viral population.